In short
This article discusses the clinical trials of AAVAnc80-hOTOF, a promising gene therapy for individuals with sensorineural hearing loss caused by mutations in the otoferlin gene (OTOF). The trials aim to evaluate the safety, tolerability, and effectiveness of this innovative treatment approach for patients with a specific type of genetic hearing loss.
At a glance
- Treatment
- AAVAnc80-hOTOF gene therapy
- Target Condition
- Otoferlin gene-mediated sensorineural hearing loss
- Trial Phases
- Phase 1/2 and Long-term Follow-up
- Age Group
- 2-17 years old
- Administration
- Intracochlear injection
- Primary Objectives
- Safety, tolerability, and bioactivity assessment
- Secondary Objectives
- Efficacy evaluation, including changes in hearing thresholds
- Key Eligibility Criteria
- Confirmed biallelic OTOF mutations, profound bilateral hearing loss, preserved otoacoustic emissions
- Follow-up Duration
- Extended long-term follow-up study
What is AAVAnc80-hOTOF?
AAVAnc80-hOTOF is an exciting new gene therapy being developed to treat a specific type of hearing loss called otoferlin gene-mediated hearing loss. This therapy is designed to help people who have hearing problems because of mutations in their otoferlin gene (OTOF).
How Does It Work?
AAVAnc80-hOTOF uses a special type of virus called AAV (adeno-associated virus) to deliver a healthy copy of the otoferlin gene to the inner ear. The therapy consists of two parts:
- AAVANC80-5'HOTOF: This is one part of the gene therapy.
- AAVANC80-3'HOTOF: This is the other part of the gene therapy.
Together, these two parts carry the complete instructions for making the otoferlin protein, which is essential for normal hearing.
Who Can Benefit from This Treatment?
This therapy is being developed for people who have profound bilateral sensorineural hearing loss due to mutations in both copies of their otoferlin gene. The current clinical trial is focusing on:
- Children aged 7 to 17 years old for the initial group
- Children aged 2 to 17 years old for later groups
To be eligible, patients must have confirmed mutations in their OTOF gene and show signs of profound hearing loss, such as no response to loud sounds in hearing tests.
Clinical Trials
AAVAnc80-hOTOF is currently being studied in clinical trials to determine its safety and effectiveness. The main trial is a Phase 1/2 study that aims to:
- Assess the safety and tolerability of different doses of AAVAnc80-hOTOF
- Measure how well the therapy improves hearing
How is AAVAnc80-hOTOF Administered?
AAVAnc80-hOTOF is given as a one-time treatment directly into the inner ear. This is called an intracochlear administration. The procedure involves:
- A surgical procedure under general anesthesia
- Use of a special delivery device to inject the therapy into the cochlea (the part of the inner ear responsible for hearing)
Safety and Efficacy
The main goals of the current clinical trial are to evaluate:
- The safety of AAVAnc80-hOTOF, including any side effects
- How well the therapy improves hearing, measured by various hearing tests
Researchers will be closely monitoring participants for any adverse events and checking their hearing regularly to see if there are improvements.
Long-Term Follow-Up
Because AAVAnc80-hOTOF is a new type of treatment, it's important to monitor its long-term effects. A separate long-term follow-up study is planned to:
- Evaluate the long-term safety of AAVAnc80-hOTOF, including any late-occurring side effects
- Assess how well the hearing improvements are maintained over time
This follow-up study will involve regular check-ups and hearing tests for participants who received AAVAnc80-hOTOF in the initial clinical trial.
AAVAnc80-hOTOF represents an exciting potential breakthrough for people with otoferlin-mediated hearing loss. While it's still in the testing phase, this gene therapy offers hope for a future where this type of genetic hearing loss could be treated effectively.